Drug name - Dificid
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8586551 | CUBIST PHARMS LLC | 18-membered macrocycles and analogs thereof |
Jul, 2023
(7 months from now) | |
| US7378508 | CUBIST PHARMS LLC | Polymorphic crystalline forms of tiacumicin B |
Jul, 2027
(4 years from now) | |
| US7863249 | CUBIST PHARMS LLC | Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof |
Jul, 2027
(4 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8586551
(Pediatric) | CUBIST PHARMS LLC | 18-membered macrocycles and analogs thereof |
Jan, 2024
(1 year, 1 month from now) | |
| US7906489 | CUBIST PHARMS LLC | 18-membered macrocycles and analogs thereof |
Mar, 2027
(4 years from now) | |
| US8859510 | CUBIST PHARMS LLC | Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof |
Jul, 2027
(4 years from now) | |
| US7863249 | CUBIST PHARMS LLC | Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof |
Jul, 2027
(4 years from now) | |
|
US7906489
(Pediatric) | CUBIST PHARMS LLC | 18-membered macrocycles and analogs thereof |
Sep, 2027
(4 years from now) | |
|
US8859510
(Pediatric) | CUBIST PHARMS LLC | Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof |
Jan, 2028
(5 years from now) | |
|
US7378508
(Pediatric) | CUBIST PHARMS LLC | Polymorphic crystalline forms of tiacumicin B |
Jan, 2028
(5 years from now) | |
|
US7863249
(Pediatric) | CUBIST PHARMS LLC | Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof |
Jan, 2028
(5 years from now) | |
| US9808530 | CUBIST PHARMS LLC | Composition of tiacumicin compounds |
May, 2034
(11 years from now) | |
|
US9808530
(Pediatric) | CUBIST PHARMS LLC | Composition of tiacumicin compounds |
Nov, 2034
(11 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Patient Population (NPP) | Jan 24, 2023 |
| Orphan Drug Exclusivity (ODE) | Jan 24, 2027 |
| Pediatric Exclusivity (PED) | Jul 24, 2023 |
Drugs and Companies using FIDAXOMICIN ingredient
Market Authorisation Date: 27 May, 2011
Treatment: Treatment of microbial infections; Treatment of clostridioides difficile-associated diarrhea (cdad) in patients from 6 months of age and older
Dosage: TABLET;ORAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| 200MG | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.